Summary of Dyadic International Conference Call Company Overview - **Company**: Dyadic International (Ticker: DYAI) - **Industry**: Biotechnology, specifically focusing on recombinant proteins and enzymes for life sciences, food, nutrition, and bioindustrial applications - **Key Personnel**: Joe Hazelton, President and COO, with prior experience at Novartis Pharmaceuticals [2][3] Core Points and Arguments - **Strategic Shift**: Dyadic has transitioned from a platform-based organization to a product-focused company, emphasizing high-growth non-therapeutic markets to generate revenue more quickly and reliably [2][3][4] - **Technology Platforms**: The company utilizes two main platforms: - **C1 Adaptabus**: Focused on producing high-yield, animal-free recombinant proteins for life sciences and biopharmaceuticals [3][4] - **Dapivis**: Designed for food, nutrition, and bioindustrial markets, offering lower-cost production of proteins and enzymes [8][9] - **Market Opportunities**: Dyadic targets a total addressable market of approximately $25 billion across various sectors, including life sciences, food, nutrition, and bioindustrial applications [4][32] - **Revenue Generation**: The company is moving towards commercialization with initial revenue streams from partnerships and product launches expected in 2025 and beyond [11][12][35] Financial Projections - **Cash Flow Positive**: Dyadic anticipates becoming cash flow positive by the end of 2026, with a low annual burn rate of $4 million to $5 million [34][35] - **Revenue Ramp**: The company expects significant revenue growth driven by partnerships, particularly in the cell culture media market, which is projected to be a billion-dollar opportunity [36][37] Market Segments and Products - **Life Sciences**: Targeting a $10 billion market, focusing on cell culture media, diagnostics, and therapeutic proteins [8][12] - **Key Products**: Recombinant human albumin, transferrin, and growth factors, which are critical for biomanufacturing [14][15] - **Food and Nutrition**: Estimated at $11 billion, focusing on non-animal dairy and functional proteins [17][18] - **Partnerships**: Collaborations with companies like Enzymes for non-animal dairy enzymes, with expected product launches in late 2025 [17][28] - **Bioindustrial**: Aiming for a $100 billion market, focusing on enzymes for biomass conversion and other industrial applications [10][20] Competitive Advantages - **High Yield and Low Cost**: Dyadic's platforms are designed to produce high-quality, sustainable, and ethically sourced proteins at competitive costs, addressing the market shift towards non-animal solutions [6][32] - **Faster Time to Market**: The company emphasizes shorter development cycles compared to traditional biopharmaceuticals, allowing for quicker revenue generation [11][24] Partnerships and Collaborations - **Strategic Partnerships**: Dyadic has established partnerships with key players in the industry, such as Proliant Health and Biologicals, to leverage their distribution networks and expertise [13][36] - **Funding and Grants**: The company has secured funding from organizations like the Gates Foundation and is involved in initiatives like the European Vaccine Hub, which supports its biopharmaceutical programs [30][31] Conclusion - **Inflection Point**: Dyadic is at a critical juncture, transitioning from R&D reliance to active commercialization of products, with a strong focus on non-therapeutic markets that promise quicker revenue streams [33][34] - **Future Outlook**: The company is optimistic about its growth trajectory, with expectations of profitability within three years as it capitalizes on its innovative platforms and market opportunities [35][37]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 increased to $967,000 compared to $386,000 for the same period a year ago, driven by milestone revenue and grant revenue [20] - Net loss for the quarter decreased to $1,794,000 or $0.06 per share compared to $2,045,000 or $0.07 per share for the same period a year ago [23] Business Line Data and Key Metrics Changes - Research and development expenses increased to $629,000 compared to $516,000 for the same period a year ago, driven by more active internal research initiatives [21] - General and administrative expenses decreased to $1,004,000 compared to $1,608,000 for the same period a year ago, reflecting reductions in various expense categories [22] Market Data and Key Metrics Changes - The global market for bioindustrial enzymes for biofuels and biogas is approximately $10 billion, with significant opportunities in Asia Pacific and India [34] - The life sciences market for recombinant products is estimated to be approximately $5 billion to $6 billion, with albumin, transferrin, and growth factors being the top three revenue products [65] Company Strategy and Development Direction - The company has transitioned from a technology-focused R&D organization to a market-facing revenue-driven biotechnology business, emphasizing high-growth non-therapeutic markets [4][5] - The rebranding to Dyadic Applied Biosolutions reflects a sharpened mission to deliver applied biotechnology solutions for non-animal derived proteins and enzymes [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capture meaningful opportunities in the life sciences, food nutrition, and bioindustrial markets, with commercial launches approaching [69] - The company aims to be cash flow positive by 2026, with increased profitability expected in 2027 and beyond [53] Other Important Information - The company completed a $5.3 million equity raise on August 1, 2025, to fund late-stage product development and scale-up [8] - The company is actively engaged in partnerships for product development, including a $3 million grant from the Gates Foundation for monoclonal antibody development [18] Q&A Session Summary Question: What is the updated cash burn expected for this year and the next twelve months? - Management expects operating expenses to remain at or below last year's level, depending on product sales in the upcoming quarters [26][27] Question: Can you provide timelines and milestones for the commercialization of DNase one and transferrin? - DNase one is commercially ready, with research-grade product manufacturing underway, while transferrin is being evaluated for scale-up and expected to be ready by late 2025 to 2026 [29][30] Question: What is the market potential for the bioindustrial enzymes for biofuels and biogas? - The bioindustrial enzymes market is approximately $10 billion, with initial customer bases in India and Asia Pacific [34] Question: Are there any conflicts with DuPont regarding industrial activities? - There are no conflicts as the company is using DAPIVIS for industrial products, and the non-compete agreement with DuPont has expired [45][46] Question: When will the company be cash flow positive? - The goal is to achieve cash flow positivity by 2026, with increased profitability anticipated in 2027 and beyond [53]

Core Viewpoint - Dyadic International, Inc. is transitioning from a technology development organization to a market-facing, revenue-focused biotechnology company, with significant advancements in its life sciences and nutrition pipelines, and a recent capital raise to support this shift [2][4]. Company Developments and Updates - The company completed a strategic leadership and operational transformation, rebranding as Dyadic Applied BioSolutions to emphasize commercial execution [4]. - Dyadic raised $5.3 million through an equity offering to enhance liquidity and fund pipeline and commercial growth [4][11]. - As of June 30, 2025, the company reported cash and equivalents of $7.3 million, down from $9.3 million at the end of 2024 [10]. Financial Highlights - Total revenue for Q2 2025 reached $967,000, a significant increase from $386,000 in the same period last year, driven by milestone revenues [12][13]. - Research and development expenses rose to $629,000 from $516,000 year-over-year, reflecting increased internal research initiatives [14]. - General and administrative expenses decreased by 10.6% to $1,437,000 compared to $1,608,000 in the previous year [15]. - The net loss for Q2 2025 was $1,794,000, an improvement from a net loss of $2,045,000 in the same quarter of the previous year [17]. Product Development and Partnerships - Dyadic is advancing its recombinant serum albumin and transferrin products, with expected commercial launches in 2025 [5]. - The company is also developing additional nucleic acid enzymes to meet growing demand for DNA/RNA manipulation tools, with results anticipated by late 2025 [6]. - Dyadic has achieved milestones in its partnership with the Gates Foundation, receiving $1.5 million in funding for monoclonal antibody development [12]. Market Focus - Dyadic's microbial production platforms are positioned to disrupt the cost, speed, and scalability of protein production across various markets, particularly as industries shift towards non-animal sources [2][4]. - The company is actively negotiating licensing and supply agreements for its recombinant alpha-lactalbumin and expects to launch additional non-animal dairy enzymes by late 2025 [12].